ArticleVeterinary research communications2026
First serological evidence of circulation of equine rhinitis A virus and molecular detection of equine rhinitis B virus in horses in North Africa.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Equine rhinitis A virus (ERAV) and equine rhinitis B virus (ERBV) are major respiratory pathogens of horses with a global distribution. The aim of this study was to evaluate, for the first time in Algeria, the seroprevalence of ERAV antibodies, and to investigate a wide range of equine viruses (EIV, EHV-1, EHV-4, ERAV and ERBV). A total of 298 serum samples were collected between May 2022 and October 2023, from 11 provinces. Serological analysis for the presence of ERAV was performed using the complement fixation test (CFT). Our results revealed that 16.8% (50/298) samples tested positive for antibodies to ERAV. In parallel, 23 nasal swabs (NS) collected during this period were analyzed by RT-PCR for the detection of ERAV and ERBV. In addition, 74 different sample materials (50 NS, 21 fecal samples, and 3 urine samples), were taken from horses presenting with cough and mucopurulent nasal discharge, between November 2023 and June 2025. The prevalence of equine respiratory virus infections was examined using polymerase chain reaction (PCR). One, or more, of five equine respiratory viruses were detected in the nasal swabs of 3 of 72 horses (4.2%) and the detection rate of equine herpesvirus type 4 (EHV-4) and ERBV were 4.2% and 2.8%, respectively. Unfortunately, viruses could not be sequenced due to low viral load i.e. they had high Cycle Threshold (Ct) values. Equine herpesvirus type 1 (EHV-1), equine influenza virus (EIV) and ERAV were not detected in any samples. Among the three infected horses, two were co-infected with EHV-4 and ERBV. ERAV seroprevalence possibly varied according to sampling period. This study is the first to report the circulation of ERAV and ERBV in the Algerian horse population. Further studies are necessary to isolate and obtain molecular characterisation of ERAV and ERBV from horses in Algeria. Detailed research on epidemiological risk factors for ERVs infections in horses is essential to support and improve diagnosis, prevention and control strategies against these viruses.
Indexed as
Identifiers
42313323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.